Kornimate/medical-research-clean huggingface dataset:
empathy through pain control: lidocaine gel vs. placebo prior to iud placement

Conditions: Contraception; Pain, Acute; Anesthesia, Local

Summary: the goal of this research study is to learn more about how different uses of a numbing medication might affect pain levels while getting an iud placed. the investigators are also studying patients' opinions of their clinicians' empathy. the investigators are inviting patients who have never given birth who arrive at their clinic visit seeking an iud. usually, at university of california, san diego (ucsd), for patients who have never delivered, clinicians numb both the sides of the cervix with a lidocaine-based paracervical block. the purpose of this research study is to compare perceptions of pain between lidocaine-infused gel and non-medicated gel inserted into the vagina before paracervical block and iud placement for nulliparous women.

lidocaine jelly is a substance that has been approved by the food and drug administration (fda). at ucsd and other places, it is not currently standard practice for people with prior deliveries birth to receive any sort of vaginal jelly before paracervical block prior to iud placement. participants who take part in this study, may receive 6cc of 2% lidocaine gel or 6cc of a non-medicated gel in the vagina before a paracervical block for iud placement. throughout the local anesthetic and intrauterine device (iud) placement procedure, research team members will present participants with questionnaires to complete to assess participants' pain, participants' satisfaction with the procedure, and how much empathy participants feel the clinician has shown.

Eligibility criteria:
inclusion criteria: 1. ability to provide informed consent 2. women presenting for iud placement for contraception or heavy menstrual bleeding 3. ages 18-50 4. english-speaking 5. participants must not have a past medical history of substance use disorders, pain disorders, use of prescription pain medications or are found to be pregnant 6. nulliparous (never given birth) exclusion criteria: 1. history of ever giving birth 2. current use of prescription pain medication prior to procedure. over-the-counter medications such as those containing ibuprofen, aspirin, acetaminophen, or naproxen are allowed. 3. diagnosed chronic pain condition 4. current pregnancy 5. known allergic reactions to components of the local anesthetic 6. history of an iud placement 7. current substance use or history of substance use 8. known contraindications to iud, such as unexplained vaginal bleeding
low dose rituximab as a first line biologic therapy for the treatment of dmard resistant patients with rheumatoid arthritis

Conditions: DMARD Resistant Rheumatoid Arthritis

Summary: in this project the investigators decide to evaluate the efficacy and safety of half dose mabthera (it means 500 mg infusion two weeks apart) in conventional drug resistant cases of rheumatoid arthritis. the investigators choose this drug because the use of anti-tnf drugs limited in the investigators refractory patients as the first line drugs because of its cost.


Eligibility criteria:
inclusion criteria: * 1987 acr criteria for classification of ra * positive for rheumatoid factor(rf) * active ra despite therapy with conventional for at least 3 months as evidenced by das 28 \> 3/2 * patients with active, resistant ra who didn't receive anti tnf agents. exclusion criteria: * patient with hypogammaglobulinemia * patient with congestive heart failure (classiv) * active current bacterial,viral,fungal,myocardial or other infections * chronic hepatitis b or hepatitis c carriers * history of severe allergic reaction to human,humanized or murine monoclonal antibodies * history of malignancies * pregnant women or lactating mothers 8) patients with chronic renal failure and hepatic disease.

Keywords: rituximab rheumatoid arthritis biologics anti-tumour necrosis factor disease-modifying anti-rheumatic drugs das28 european league against rheumatism response
analysis of risk factors for hearing loss in survivors of cancer occurred during childhood, adolescence or young adulthood

Conditions: Ototoxicity, Drug-Induced; Ototoxicity, Radiation-Induced; Pediatric Cancer

Summary: this study is aimed at people treated for cancer before the age of 25, who have been followed for at least 5 years, and who are now aged between 18 and 50. it is a prospective, multicenter, non-randomized study. the main aim of the project is to identify hearing impaired patients using the iaudiogram medical device, and to analyze the risk factors associated with the risk of hearing impairment. around 500 patients will take part in this study in france. participation in this research project will consist in carrying out a hearing test (audiogram with tonal audiometry) with the iaudigram medical device (at gustave roussy, curie or necker hospital) and completing self-questionnaires focusing on ototoxicity and its consequences.


Eligibility criteria:
inclusion criteria: * patients aged between 18 and 50 years at audiological investigations * treated for brain tumor, solid cancer, lymphoma or leukemia in childhood, adolescence or at a young adult age (\<25years) * with at least 5 years of cancer-free follow-up after childhood cancer * patients included in the fccss ( https://fccss.fr ) deep cohort of 7670 5-year childhood cancer survivors treated before 2001, or patients who have planned visit in long-term follow-up clinics of curie institute and gustave roussy, whatever the diagnostic period * pregnant or breast-feeding women can be included as no risk is identified * with social security coverage * signed written informed consent obtained nb: patients included in another research project are not excluded from this one nb: patients wearing a lyric hearing prosthesis or any other permanent hearing prosthesis or cochlear implant can be included in the study but will not perform audiological examinations because the audiogram can't be easily performed without hearing prosthesis. nevertheless, these patients could participate to the study with self-administered questionnaires and could be included as cases (i.e. patients with hearing deficiency) in analyses. exclusion criteria: * patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent * patient with unavailable data concerning treatment modalities including cumulative doses of chemotherapy agents or radiation fields and dose
a new piezoelectric technique in third molar surgery

Conditions: Tooth Diseases; Piezoelectric Technique; Tooth, Impacted; Tooth Extraction Status Nos; Tooth Avulsion; Facial Swelling

Summary: the present study aims to analyze the effect of the piezoelectric technique in third molar surgery in terms of facial swelling, trismus and pain in a split-mouth randomized controlled clinical trial

the present study aims to analyze the effect of of the piezoelectric technique n third molar surgery in terms of facial swelling, trismus and pain in a split-mouth randomized controlled clinical trial. facial swelling will be assessed using an innovative three-dimensional digital technique.

Eligibility criteria:
inclusion criteria: * patients aged 18 to 32 years who required both m3m extractions were recruited * good health status * indication to surgical extraction of both m3m * complete root formation * surgical risk level classified as "conventional" or "moderate" according to - daugela et al. classification exclusion criteria: * person under the age of 18 or over 32 * allergy or contraindications to administration of corticosteroids * acute infection in any of the teeth to be extracted * patients with chronic liver disease, diabetes, immune system dysfunction, or haematological disease * pregnancy or breastfeeding * history of treatment with antiresorptive drugs * chronic kidney disease

Keywords: third molar surgery facial swelling 3d facial swelling evaluation piezoelectric technique tooth impacted piezosurgery
assessment of verbal comprehension and cognitive processes in patients admitted to the palliative and supportive care unit

Conditions: Hematopoietic and Lymphoid Cell Neoplasm; Locally Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Recurrent Malignant Solid Neoplasm

Summary: this study investigates the use electroencephalography (eeg - a test that measures brain waves) to learn if patients who appear unresponsive (do not respond to noises, words, or touch) retain any consciousness. families want to know if their loved ones who are unresponsive can still hear them or feel any discomfort. information gained from this study may have important impact in how patients, caregivers, and doctors make decisions.

primary objectives: i. to estimate the magnitude of electroencephalography (eeg) response to verbal stimuli among cancer patients in the last days in life admitted to a palliative and supportive care unit (pscu). ii. to examine the feasibility of conducting eeg in cancer patients in the last days of life. secondary objectives: i. to compare the magnitude of eeg response between impending death cohort and control cohort. ii. to determine the association between the magnitude of eeg response and clinical assessments (e.g. jfk coma recovery scale-revised \[crs-r\], glasgow coma scale \[gcs\], richmond agitation sedation scale \[rass\], memorial delirium assessment scale \[mdas\]) in impending death cohort and control cohort separately. iii. to determine the magnitude of eeg response to pressure/noxious stimuli in impending death cohort and control cohort separately. iv. to examine serial eeg changes in auditory cortex activation and cognitive processing in cancer patients over the last days of life. outline: patients undergo eeg over 30 minutes daily until death or discharge and complete questionnaires over 30 minutes daily until death or discharge to check level of consciousness, thought, and ability to communicate.

Eligibility criteria:
inclusion criteria: 1. \[both cohorts\] diagnosis of advanced cancer (defined as locally advanced, metastatic, recurrent, or incurable disease) 2. \[both cohorts\] admitted to the pscu at md anderson cancer center or seen by the specialist palliative care inpatient consultation team (control cohort only) 3. \[impending death cohort\] clinician judgement of .3 days of survival or .1 late sign of impending death\* 4. \[impending death cohort\] palliative performance scale score of 10-20% 5. \[control cohort\] able to communicate for the past 24 hours 6. \[control cohort\] clinician judgement of .1 month of survival 7. \[both cohorts\] english-speaking exclusion criteria: 1. \[both cohorts\] hearing impairment that significantly impacts daily communication with caregiver prior to entering impending death phase or requiring hearing aid 2. \[impending death cohort\] mental status changes only related to medications as per clinician judgement 3. \[control cohort\] diagnosis of delirium (i.e. mdas .13) 4. \[both cohorts\] pregnant women 5. \[both cohorts\] age \< 18 years old
prevalence of marginal ulcer after pppd and preventive effect of proton pump inhibitor in korea: a prospective multicenter study

Conditions: Pancretic Dissease (Benign/Malignancy); BIle Duct Diseae(Benign/Malignancy); Ampulla of Vater Disease (Benign/Malignancy)

Summary: this research is to determine which medication, esmesol (ppi) or placebo works best at reducing the chance that a patient will get an marginal ulcer after pancreaticoduodenectomy.


Eligibility criteria:
inclusion criteria: * subject is age ≥ 19 years patient meets the criteria for open/mis pppd females only: patient is willing to take a urine pregnancy test exclusion criteria: - subject allergic to esmesol patient receiving antifungal (i.e. ketoconazole or itraconazole) hepatic insufficiency history of crohns disease history of zollinger-ellison disease patient received an investigational drug within 30 days of enrollment previous gastric surgery hx
determine the main muscle participant in the deformation of the elbow in hemiplegic patients

Conditions: Hemiplegia

Summary: the aim of this study is to determinate what are the main muscles regularly involved in the spastic pattern in flexion of the elbow using the selective motor nerve blocks of the elbow flexors. three selective motor block nerves will be carry out in order to assess the gain of the range of motion (passive and active) of the elbow after each motor block nerve.

to assess the impact of selective motor block nerves (successively brachialis motor branch, radialis motor nerve and musculocutaneous motor branch) on passive and active ranges of motion of the elbow in stroke patients with spastic flexion pattern. procedure: following the morphological landmarks already described, the brachialis motor nerve of 30 patients was blocked with 4cc of lidocaïne® 1% (electro stimulation 0.8 to 1ma) (ref). twenty minutes after the injection, the measurement of the degree of the spasticity, the passive angle in extension and the active range of motion in flexion of the elbow were performed. then the radialis motor nerve block was performed (at the union of the median third and lower third of the arm, medial view, 3 finger widths above the medial epicondyle) using the same procedure, in order to block the brachioradialis and the brachialis in case of double innervation. twenty minutes after the injection, the measurement of the passive and active ranges of motion of the elbow was performed. at the end the musculocutaneous motor block nerve was performed (proximal quarter of the arm, medial view, at the base of the inferior limit of the pectoralis major and along the biceps brachii tendon) in order to make the final difference with muscle contracture if it existed a doubt.

Eligibility criteria:
inclusion criteria: * written consent * hemiplegic patient with spasticity and deformation of elbow exclusion criteria: * pregnant woman
a comparative study of platelet-rich plasma and normal saline dressings in the treatment of chronic wounds (prp-ns wound t)

Conditions: Wound Healing

Summary: this study aims to compare the effectiveness of platelet-rich plasma (prp) dressings versus normal saline dressings in the treatment of chronic wounds. chronic wounds are slow-healing wounds that can cause significant discomfort, increase the risk of infections, and impact a patient's quality of life. platelet-rich plasma (prp) is derived from the patient's own blood and contains growth factors that may help promote faster wound healing. on the other hand, normal saline dressings are commonly used as a standard wound care approach. participants in this study will be randomly assigned to receive either prp dressings or normal saline dressings. the healing progress of their wounds will be monitored over a specified period to determine which treatment leads to better and faster healing. the findings from this study may help improve wound care management and provide evidence for using prp as an effective treatment for chronic wounds.


Eligibility criteria:
inclusion criteria: * patients aged 18-60 years of either gender were included if they had a chronic wound persisting for at least six weeks and with a size of at least 2 × 2 cm. exclusion criteria: * patients were excluded if their wounds had existed for less than six weeks, if they had a previous history of prp dressing use, or if they had documented hypersensitivity to prp.
high dose nimodipine treatment adjunct - 1

Conditions: Cocaine-Related Disorders

Summary: the purpose of this study is to determine if nimodipine is more effective than placebo in reducing stimulated craving for cocaine in cocaine dependent individuals denied access to cocaine in inpatient unit.


Eligibility criteria:
please contact site for information.
combination chemotherapy in treating patients with stage ii or stage iii multiple myeloma

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. it is not yet known which combination chemotherapy regimen is more effective for multiple myeloma. purpose: this randomized phase iii trial is comparing two combination chemotherapy regimens to see how well they work in treating patients with stage ii or stage iii multiple myeloma.

objectives: * compare the partial and complete response rates in patients with multiple myeloma treated with induction therapy comprising idarubicin and dexamethasone vs vincristine, doxorubicin, and dexamethasone. * compare the disease progression, time to achieve maximal response, and duration of response in patients treated with these 2 regimens. * compare the quality of life of patients treated with these 2 regimens. outline: this is a randomized, multicenter study. patients are randomized to 1 of 2 treatment arms. * arm i: patients receive oral idarubicin and oral dexamethasone daily on days 1-4. treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. patients also receive oral dexamethasone daily on days 8-11 during course 1 only. * arm ii: patients receive oral dexamethasone daily, doxorubicin iv continuously, and vincristine iv continuously on days 1-4. courses repeat as in arm i. patients receive additional dexamethasone as in arm i. patients without a maximal response after completion of course 4 may receive up to 2 additional courses. quality of life is assessed at baseline and then prior to each study course. patients are followed for survival. projected accrual: a total of 200 patients (100 per arm) will be accrued for this study within 2 years.

Eligibility criteria:
disease characteristics: * diagnosis of stage ii or iii multiple myeloma * no prior therapy except local radiotherapy to bone lesions * no indolent multiple myeloma * no monoclonal gammopathy of unknown significance patient characteristics: age: * 75 and under performance status: * not specified life expectancy: * not specified hematopoietic: * not specified hepatic: * bilirubin no greater than 2.34 mg/dl renal: * no end stage renal failure (creatinine greater than 5.65 mg/dl after rehydration) * no requirement for dialysis other: * no other medical condition that would preclude intensive treatment * not pregnant or nursing * fertile patients must use effective contraception * no other prior malignancy prior concurrent therapy: biologic therapy * see disease characteristics chemotherapy * see disease characteristics endocrine therapy * see disease characteristics radiotherapy * concurrent local radiotherapy allowed for painful lesions or lesions that appear likely to lead to an imminent fracture surgery * see disease characteristics

Keywords: stage ii multiple myeloma stage iii multiple myeloma
effects of environmental heat exposure on human multiple organ function

Conditions: Heat Stress Disorders; Wounds and Injuries; Body Temperature Changes; Multiple Organ Dysfunction

Summary: this is a randomized controlled human exposure crossover study. investigators aims to assess the acute effects of high temperature exposure and the underlying mechanisms.

the objective of this study is to study changes in functions of multiple organs under heat exposure, which mainly include changes of cardiac function and lung function. in addition, biological samples such as blood samples, nasal fluid, and urine, etc were collected to explore changes in biomarkers such as complete blood count, liver function, kidney function, and inflammatory indicators, etc. biochemical analysis and omics analysis were conducted to study the changes of human physiological function caused by heat exposure.

Eligibility criteria:
inclusion criteria: 1. chinese nationality（aged 18-30 years healthy males and females）; 2. with ability to read and understand chinese smoothly; 3. living in jinan during the study period; 4. body mass index ≥ 18.5 and ≤ 28; 5. normal resting ecg； 6. normal lung function: i. forced vital capacity (fvc)≥80% of that predicted for gender, ethnicity, age and height; ii. forced expiratory volume in one second (fev1) ≥80% of that predicted for gender, ethnicity, age and height; iii. fev1/fvc ratio≥80% of predicted values. exclusion criteria: 1. medications or dietary supplements intake that may alter body temperature during the study period; 2. individuals who have unspecified illnesses, which in the judgment of the investigators might increase the risk associated with heat exposure will be a basis for exclusion; 3. subjects with anemia, needle fainting and other signs unsuitable for blood drawing； 4. subjects with cardiovascular diseases or other chronic medical condition, such as congenital heart disease, pulmonary heart disease, and hypertension, etc; 5. subjects with a history of major cardio-vascular, respiratory, or nervous system surgery, etc; 6. subjects with neurologic disorders, such as stroke, traumatic brain injury, epilepsy, and depression; 7. subjects with allergic diseases, such as allergic rhinitis and allergic asthma, etc; 8. subjects are pregnant, attempting to become pregnant or breastfeeding; 9. subjects who are currently smoking (including vaping, hookah and e-cigarette) or have smoking history within 1 year of study (defined as more than 1 pk/yr in the past year) or have a greater than equal to a 5 pack year smoking history; 10. subjects living with a smoker who smokes inside the house; 11. subjects who are current drinking or have frequent alcohol use (defined as at least 1 time per week) in the past 6 months; 12. provisional exclusion criteria, such as acute infection in the past two weeks or taking antibiotics. (subjects can be enrolled after 2 weeks)
testosterone and weight loss

Conditions: Obesity in Men

Summary: the investigators hypothesise that testosterone therapy will synergize with dietary intervention to achieve weight loss. obese men will receive diet, and be randomised to either testosterone therapy or placebo. primary outcomes will be weight and body composition.


Eligibility criteria:
inclusion criteria: * bmi \>30 exclusion criteria: * contraindications to testosterone therapy
effect of vestibular rehabilitation - a randomized controlled trial

Conditions: Dizziness; Nausea; Nystagmus; Vestibular Diseases

Summary: the aim of this study is to assess if early supported vestibular rehabilitation can reduce dizziness and improve daily life activities in patients with acute vestibular injury. the study question is: does early supported vestibular rehabilitation have an additional effect on dizziness symptoms and daily life functions compared to standard treatment?


Eligibility criteria:
inclusion criteria: * acute symptoms of dizziness, nausea and nystagmus * diagnosed by videonystagmography (at least 25% reduced caloric response in one ear) * age 18-70 years * inclusion within one week after symptom debut exclusion criteria: * chronic dizziness * psychiatric diagnosis that might interfere with participation

Keywords: vestibular rehabilitation acute vestibular injury dizziness nausea nystagmus daily life activities balance physiotherapy